Short-Term Oral Sorafenib for Therapy of Intratumoral Shunts of Hepatocellular Carcinoma to Enable Intraarterial Treatment.

Johannes ThueringM ZimmermannP BrunersF PedersoliM Schulze-HagenE BarzakovaC K KuhlP Isfort

Published in: Cardiovascular and interventional radiology (2019)

Even short-term oral sorafenib seems to effectively close intratumoral shunts in patients with HCC and thus might enable transarterial treatment of these patients.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
stem cells
prognostic factors
bone marrow
mesenchymal stem cells
replacement therapy